2018 Pharmaceutical Companies Vaccines 
Pharmacy Is Right For Me
AUGUST 10, 2022
Dr. Brown is the National Field Director for Janssen Infectious Diseases & Vaccines. I have been in the pharmaceutical industry since 2007 and have been in various roles involving medical affairs and research and development. From 2015 through Jan 2018, I served as the U.S. What makes your career path unique?
Pharmaceutical Technology
AUGUST 1, 2022
Since 2020, government agencies have provided funding for expensive late-stage vaccine development and the expansion of manufacturing capacity, as well as other key pharmaceutical activities. The shift from private to public funding enabled more rapid development of Covid-19 drugs and vaccines.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
European Pharmaceutical Review
OCTOBER 24, 2022
The report found that consistently slow and variable study setup and recruitment timelines in the NHS are forcing some pharmaceutical companies to place their trials in other countries. This had increased by 25 days since 2018, which dropped the UK to 7 th place amongst comparator countries. “The
pharmaphorum
DECEMBER 15, 2020
There is a long-established synergistic relationship between larger, “innovation-driven” pharmaceutical companies and the generics industry in ensuring supply of established, but nevertheless essential, medicines. The pandemic has further highlighted how research is not strictly limited to large, “innovator” pharmaceutical companies.
pharmaphorum
NOVEMBER 4, 2022
BioNTech and Pfizer have announced that they are initiating a phase 1 study to evaluate a single dose mRNA-based combination vaccine candidate against influenza and COVID-19 – a novel combination approach to help protect individuals against two severe respiratory viral diseases in one dose.
pharmaphorum
JULY 14, 2021
As we come up on a year and a half of the COVID-19 pandemic, with the global roll out of vaccines slowly gathering pace and big pharma riding high in the opinion charts, the biopharmaceutical sector would do well to learn lessons from the banks. Compliance systems by themselves are not enough.
pharmaphorum
AUGUST 5, 2022
The pace of innovation in biopharma has rocketed over the last two years, with vaccines, new antivirals, and therapies delivered at an unprecedented pace. And, for M&A deals valued at more than $500M, the average takeout premium in biopharma has grown from 51% in 2018, to roughly 71% in 2021. About the Author.
Expert insights. Personalized for you.
130 
Let's personalize your content